Legend Biotech (LEGN) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Legend Biotech Corporation  (NASDAQ: LEGN)


Legend Biotech's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Legend Biotech's ROA in the fourth quarter of 2025?
Legend Biotech Corporation recorded a cumulative net loss of $-297 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -17.53%.

However, within the Healthcare sector 400 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 3983.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 4.37 % -7.11 % 5.96 % -29.31 % -9.82 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -297 -240 -325 -218 -177
Return On Assets (TTM) -17.53 % -14.31 % -19.05 % -12.95 % -9.56 %
LEGN's Total Ranking # 3983 # # # # 3880
Total Assets (TTM) in million 1,756 1,713 1,690 1,616 1,682
Seq. Total Assets Change 2.5 % 1.36 % 4.6 % -3.96 % -8.77 %
Seq. Net Income Change - - - - -

LEGN's 5 Years Annual ROA >> Back to LEGN Management Effectiveness >> Compare LEGN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 151
Sector # 401
Overall # 3946

Return On Assets Statistics
High Average Low
-10.6 %
-25.07 %
-36.05 %
(Dec 31 2024)   (Dec 31 2021)



  News about Legend Biotech Corporation Return on Assets ROA

Legend Biotech Appoints Alan Bash as President of CARVYKTI

Legend Biotech’s Strategic Appointments and Innovations in Cell TherapyIntroductionIn a rapidly transforming pharmaceutical landscape, Legend Biotech Corporation is making significant strides to solidify its position as a leader in cell therapy. Recent developments have highlighted both the challenges the company faces in terms of financial performance and the proactive measures it is taking to drive growth and innovation.Executive Appointment to Drive GrowthOn October 3, 2024, Legend Biotech announced the appointment of Alan Bash as President of CARVYKTI, a newly created position aimed at sharpening the company s focus on growth and sales. This appointment comes at a critical time as the company strives to enhance its market presence and address the challenges posed by a cumulative net loss of $518 million over the previous 12 months, culminating in a negative return on assets (ROA) of -28.03%.



Financial Statements
Legend Biotech's Assets $ 1,756 million LEGN's Balance sheet
Legend Biotech's Income $ -31 million Quarterly LEGN's Income Statement
LEGN's Income by Division See LEGN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 4.37 % -9.82 % 104.34 % -17.21 % 54.44 %
Total Assets in million 1,756 1,682 1,865 913 1,103
Y / Y Net Income Change - - - - -
Net Income in million -297 -177 -518 -446 -404
Annual Return On Assets -16.9 % -10.52 % -27.78 % -48.89 % -36.6 %

LEGN's 5 Years Annual ROA >> Back to LEGN Management Effectiveness >> Compare LEGN ROA to its Competitors



More Return On Assets Ratios
LEGN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LEGN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LEGN's Competitors
Subscribers only: Roa for Legend Biotech's Suppliers
Subscribers only: Return On Assets for LEGN's Customers

You may also want to know
LEGN's Roi LEGN's Inventory Turnover Ratio LEGN's Growth Rates LEGN's Dividend Comparisons
LEGN's Profitability Ratios LEGN's Asset Turnover Ratio LEGN's Dividend Growth
LEGN's Roe LEGN's Valuation Ratios LEGN's Financial Strength Ratios LEGN's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA

Date modified: 2026-09-08T18:38:39+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.